Related Experiment Videos
Hepatitis C infection: a clinical review
1Center for Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312, USA. brianpearlman@hotmail.com
Southern Medical Journal
|April 28, 2004
Summary
Hepatitis C (HCV) affects millions, with rising chronic liver disease despite falling incidence. Standard treatment with pegylated interferon and ribavirin offers a 55% cure rate for treatment-naïve patients, but carries side effects.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) infection impacts nearly three million individuals in the U.S.
- Despite declining incidence, HCV-related chronic liver disease prevalence is increasing.
- Intravenous drug use is the primary transmission route in the United States.
Purpose of the Study:
- To summarize the epidemiology, diagnosis, and current treatment standards for chronic Hepatitis C virus (HCV).
- To highlight the long-term risks associated with HCV chronicity and progression to advanced liver disease.
- To review the efficacy and common side effects of standard HCV therapy.
Main Methods:
- Literature review of epidemiological data on HCV prevalence and incidence.
- Analysis of diagnostic methods, focusing on enzyme immunoassay specificity.
- Evaluation of treatment outcomes for pegylated interferon and ribavirin therapy.
Main Results:
- HCV chronicity affects up to 85% of infected individuals, with a 20% risk of advanced liver disease within 20 years.
- Third-generation enzyme immunoassays demonstrate >99% specificity in immunocompetent patients.
- Pegylated interferon and ribavirin achieve approximately 55% cure rates in treatment-naïve patients, with notable side effects.
Conclusions:
- Hepatitis C virus (HCV) remains a significant public health concern due to increasing chronic liver disease.
- Early diagnosis and treatment are crucial to mitigate long-term complications.
- Current standard therapies offer moderate cure rates but require careful management of adverse effects.